Enanta Pharmaceuticals (ENTA) Interest & Investment Income (2012 - 2026)
Enanta Pharmaceuticals (ENTA) posted Interest & Investment Income of $2.1 million for Q1 2026, down 13.96% on a QoQ basis from $2.4 million in Q4 2025, and down 9.08% year-over-year from $2.3 million in Q1 2025.
Enanta Pharmaceuticals (ENTA) Interest & Investment Income (2012 - 2026) Analysis & Trends
Enanta Pharmaceuticals' Interest & Investment Income history runs 10 years deep, the most recent figure standing at $2.1 million for Q1 2026.
- Quarterly Interest & Investment Income fell 9.08% year-over-year to $2.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.9 million (down 24.65% YoY) and the FY2025 annual result came in at $9.4 million, down 36.07% from the prior year.
- Interest & Investment Income was $2.1 million for Q1 2026 at Enanta Pharmaceuticals, down from $2.4 million in the prior quarter.
- Across five years, Interest & Investment Income topped out at $4.3 million in Q4 2023 and bottomed at $2.1 million in Q3 2025.
- A 4-year average of $2.9 million and a median of $2.6 million in 2024 frame the typical range for Interest & Investment Income.
- Annual changes were most pronounced in 2025 — Interest & Investment Income slumped 39.83% — and 2026, when it fell 9.08%.
- Enanta Pharmaceuticals' Interest & Investment Income stood at $4.3 million in 2023, then tumbled by 34.88% to $2.8 million in 2024, then dropped by 13.47% to $2.4 million in 2025, then decreased by 13.96% to $2.1 million in 2026.
- Business Quant data shows ENTA's Interest & Investment Income at $2.1 million in Q1 2026, $2.4 million in Q4 2025, and $2.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 27.66 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 114.80 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -65.80 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 44.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 19.51 Mn |
| 10 | Enanta Pharmaceuticals | 369.97 Mn | 206.20 Mn | - | 2.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.08 Mn |
| Dec 31, 2025 | 2.42 Mn |
| Sep 30, 2025 | 2.07 Mn |
| Jun 30, 2025 | 2.29 Mn |
| Mar 31, 2025 | 2.29 Mn |
| Dec 31, 2024 | 2.80 Mn |
| Sep 30, 2024 | 3.18 Mn |
| Jun 30, 2024 | 3.49 Mn |
| Mar 31, 2024 | 3.81 Mn |
| Dec 31, 2023 | 4.30 Mn |
| Dec 31, 2017 | 928,000.00 |
| Sep 30, 2017 | 783,000.00 |
| Jun 30, 2017 | 628,000.00 |
| Mar 31, 2017 | 572,000.00 |
| Dec 31, 2016 | 549,000.00 |
| Sep 30, 2016 | 497,000.00 |
| Jun 30, 2016 | 474,000.00 |
| Mar 31, 2016 | 408,000.00 |
| Dec 31, 2015 | 356,000.00 |
| Sep 30, 2015 | 308,000.00 |